Even when researchers removed blurry or low-quality scans, the link between IGF-I and muscle energy recovery stayed strong — so the finding is reliable.

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Randomized Controlled Trial

Human

2014 Jan

The study found that when obese people with low growth hormone took tesamorelin, their muscle energy recovery improved, and this improvement was linked to higher IGF-I levels — even after accounting for other factors, so it’s unlikely that scan quality messed up the results.

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Source Study

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Score: 61

DOI: 10.1210/jc.2013-3436

Similar Assertions

In people who took tesamorelin, the more their IGF-I levels went up, the better their muscles recovered after exercise — and this link was even stronger than in the whole group.

90%

Even though the drug raised IGF-I levels, it didn’t make the muscle energy recovery noticeably better than the placebo — so the effect might be subtle or only show up in certain people.

89%

In people who took the placebo, IGF-I didn’t go up much, and their muscle energy recovery didn’t link to IGF-I — meaning the connection only showed up when the drug raised IGF-I.

87%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole study group.

83%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.

82%